Vaccinex Inc (VCNX)
$2.76
+0.23
(+9.09%)▲
Live
Performance
- $2.56$2.76$2.76
7.25%
Downside
Day's Volatility :7.25%
Upside
0.0%
- $1.39$15.91$2.76
49.64%
Downside
52 Weeks Volatility :91.26%
Upside
82.65%
Returns
| Period | Vaccinex Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -67.1% | 0.0% |
6 Months | -48.79% | 0.0% |
1 Year | -81.37% | 0.0% |
3 Years | -99.37% | -23.0% |
Highlights
Market Capitalization | 6.6M |
Book Value | -$2.68 |
Earnings Per Share (EPS) | -3.96 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2466.38% |
Return On Assets TTM | -495.64% |
Return On Equity TTM | -759.09% |
Revenue TTM | 356.0K |
Revenue Per Share TTM | 0.32 |
Quarterly Revenue Growth YOY | -81.10000000000001% |
Gross Profit TTM | -13.7M |
EBITDA | -21.5M |
Diluted Eps TTM | -3.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 153.62%
Technicals Summary
Sell
Neutral
Buy
Vaccinex Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vaccinex Inc | -43.65% | -48.79% | -81.37% | -99.37% | -99.78% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vaccinex Inc | NA | NA | NA | 0.0 | -7.59 | -4.96 | NA | -2.68 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vaccinex Inc | Buy | $6.6M | -99.78% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Vaccinex Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 20.0K → 232.0K (in $), with an average increase of 68.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -3.31M → -5.63M (in $), with an average decrease of 31.0% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 163.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.2%
Institutional Holdings
Point72 Asset Management, L.P.
6.75%AIGH Capital Management, LLC
6.31%Armistice Capital, LLC
5.44%Tower Research Capital LLC
0.08%Morgan Stanley - Brokerage Accounts
0.06%
Company Information
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
Organization | Vaccinex Inc |
Employees | 37 |
CEO | Dr. Maurice Zauderer Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.76
+9.09%
Invesco Bulletshares 2025 Hi
$2.76
+9.09%
Schwab International Dividend Equity Etf
$2.76
+9.09%
Blockchain Coinvestors Acquisition Corp.
$2.76
+9.09%
Allgiant Travel Company
$2.76
+9.09%
Rogers Corp
$2.76
+9.09%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.76
+9.09%
Iheartmedia
$2.76
+9.09%
Lightpath Technologies Inc
$2.76
+9.09%